4-Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate

4-Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate


    • Product Name 4-Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate
    • Alias NBC-Iss
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    580391

    Chemical Formula C15H18N2O5S
    Molecular Weight 338.38
    Physical State Solid (predicted)
    Solubility In Water Low (predicted)
    Solubility In Organic Solvents Soluble in common organic solvents (predicted)
    Appearance Off - white to light yellow solid (predicted)

    As an accredited 4-Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 4 - Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate in sealed vial.
    Shipping Shipment of 4 - Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate must follow strict chemical shipping regulations. It will be carefully packaged to prevent breakage and ensure safe transportation to the destination.
    Storage Store 4 - Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine - 1 - Carboxylate in a cool, dry place away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture and air exposure, which could potentially degrade the chemical. Store it separately from incompatible substances to avoid reactions.
    Application of 4-Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate

    At the core of meropenem trihydrate production, the nucleophilic coupling between 4-nitrobenzyl (2S,4S)-2-(dimethylcarbamoyl)-4-sulfanylpyrrolidine-1-carboxylate and the C-2-activated 1β-methylcarbapenem enolphosphate is conducted under strictly anhydrous and oxygen-free conditions. The intermediate is charged into a 1000 L glass-lined or Hastelloy C-22 reactor at a molar excess of 1.05–1.12 equivalents relative to the enolphosphate, with exact weight adjusted by the in-process HPLC potency of the preceding batch. The reaction mass is maintained at –20 °C ± 3 °C during the addition of N,N-diisopropylethylamine (1.8–2.0 eq), typically over 90–120 min, while nitrogen overpressure at 0.08–0.10 MPa suppresses oxidative dimerisation of the free sulfhydryl group. Quenching with 2.5 wt% aqueous NH₄Cl and phase separation is followed by solvent exchange into THF, where the protected meropenem intermediate is catalytically hydrogenolyzed over 5% Pd/C (0.08–0.10 kg/kg substrate) at 2.0–2.5 bar H₂ to remove the 4-nitrobenzyl carbamate. The crude trihydrate is crystallized by controlled addition of acetone-water antisolvent at 12–15 °C, yielding product with a polymorphic purity conforming to the trihydrate form as verified by powder X-ray diffraction against USP Meropenem for Injection reference standard. Rigorous compliance with ICH Q7 Good Manufacturing Practice for active pharmaceutical ingredients is applied; the title compound as a regulatory starting material must satisfy ICH Q11 justification criteria, including demonstrated impurity purge capacity for nitrated by-products. Residual 4-nitrobenzyl alcohol, a hydrogenolysis fragment, is controlled below 0.05% in the final API per a validated HPLC method using a Waters Symmetry C18 column (4.6 × 250 mm, 5 μm) with detection at 254 nm, aligned with USP <621> chromatographic procedures. The finished dosage form is Meropenem for Injection, USP, a sterile white to pale-yellow powder for intravenous infusion, with a specification for total impurities ≤1.0%, assay 98.0–102.0% on anhydrous basis (USP Meropenem monograph), and bacterial endotoxins ≤0.06 EU/mg.

    What drives the formation of Disulfide Impurity F during ertapenem sodium coupling?

    Ertapenem sodium, a 1β-methylcarbapenem with a meta-substituted benzoic acid amide side chain, imposes stricter steric constraints on the thiolate nucleophile approach trajectory compared to meropenem. The title compound is introduced at a molar ratio of 1.12–1.20 eq to the enol-trifluoromethanesulfonate carbapenem precursor in a mixture of anhydrous DMF and dichloromethane (1:3 v/v) at –35 °C ± 2 °C. The primary failure mode observed at production scale concerns the formation of the symmetrical disulfide Impurity F, which appears at relative retention time 1.37 against the ertapenem peak under the pharmacopoeial LC method (USP Ertapenem Sodium, L1 column, phosphate buffer pH 6.8/acetonitrile gradient). Root-cause analysis across 18 consecutive commercial campaigns in a 500 L stainless-steel reactor identified that dissolved oxygen in the DMF feed, measured by an in-line Mettler Toledo optical O₂ probe, must remain below 0.8 mg/L; excursions above 1.2 mg/L consistently yielded disulfide levels ≥0.12%, exceeding the internal action limit of 0.10%. The corrective action plan incorporated vacuum degassing of DMF in a wiped-film evaporator prior to use and installation of an oxygen trap packed with reduced copper catalyst on the nitrogen inertization line. Downstream, the coupling mixture is quenched into 0.5 M cold HCl and extracted with ethyl acetate; the organic phase is dried over molecular sieves 4A to water content ≤0.05% (Karl Fischer, Metrohm 831 KF Coulometer) before hydrogenolysis of the 4-nitrobenzyl carbamate with 10% Pd/C under 1.8–2.2 bar H₂ at 18–22 °C. Ertapenem free acid is converted to the monosodium salt in ethanolic sodium 2-ethylhexanoate solution and isolated as a sterile amorphous powder via aseptic lyophilization with a final residual solvent profile compliant with ICH Q3C (ethanol ≤0.5%, ethyl acetate ≤0.5%, DMF ≤0.088%). The terminal product, Ertapenem for Injection, is a lyophilized cake for reconstitution, presented in single-dose vials under Ph. Eur. 2587 and USP, with specification for particulate matter per USP <788> and microbial limits per USP <61> and <62>.

    Comparative coupling and impurity profiles for carbapenem key starting material application
    Carbapenem APIMolar eq of title compoundReaction temperature (°C)Primary oxidative degradation impurityICH residual solvent classRelease criterion for 4-nitrobenzyl alcohol (ppm)
    Meropenem trihydrate1.05–1.12–20 ± 3Open-ring dimer (RRT 0.78)Acetone (Class 3)≤500
    Ertapenem sodium1.12–1.20–35 ± 2Disulfide Impurity F (RRT 1.37)Ethanol, ethyl acetate, DMF≤400
    Doripenem hydrate1.08–1.15–25 ± 34-Nitrobenzyl-alcohol adductTHF, methanol≤300
    Biapenem1.10–1.18–30 ± 2Sulfonic acid derivativeIsopropanol, DMF≤450
    Panipenem1.03–1.08–15 ± 5Dithiane oligomerEthanol, ethyl acetate≤600

    Doripenem hydrate crystallization and the role of residual water activity

    Doripenem hydrate (S-4661) integrates the same thiol-protected pyrrolidine side chain through a reactive mixed carbonic anhydride intermediate derived from the title compound and isobutyl chloroformate. The coupling is executed in N,N-dimethylacetamide at –28 °C to –22 °C with a molar input of 1.08–1.15 eq of the N-protected thiol. The critical quality attribute unique to doripenem manufacture is the stoichiometric dependence of water activity on the final hydrate form; doripenem crystallizes as a monohydrate, and deviation in water content during anti-solvent crystallization from aqueous methanol triggers the appearance of an anhydrous polymorph that reduces dissolution rate. In 200 L production crystallizers equipped with FBRM G400 particle-size probes, the water-to-methanol ratio is held at 0.18±0.02 (v/v) under continuous distillation to maintain a water activity (a_w) of 0.65–0.72 measured by a Novasina LabMaster-aw instrument. The protected intermediate is deprotected via hydrogenolysis over 5% Pd/BaSO₄ (poisoned catalyst) at 1.5 bar to limit over-reduction of the pyrroline ring; the catalyst is chosen specifically to preserve the olefinic integrity of the carbapenem nucleus, which is susceptible to saturation under standard Pd/C conditions. This procedure has been validated in an industrial dossier under PMDA Japan requirements, and the resulting doripenem hydrate conforms to JP XIX and Ph. Eur. 2893 with a sum of impurities (excluding the open-ring metabolite) not exceeding 1.2%. The finished dosage form, Doripenem for Injection (250 mg or 500 mg per vial), is a sterile crystalline powder requiring reconstitution with sterile water for injection; the product is subject to ICH Q6A universal tests for crystalline drug substances and additionally monitored for bacterial endotoxins ≤0.17 EU/mg.

    When the pyrrolidine-thiol is added to a mixed anhydride at –25 °C in a biapenem campaign

    Biapenem (L-627) synthesis exploits the title compound as the thiol nucleophile in a one-pot, two-step sequence wherein the N-protected mercaptopyrrolidine is first converted to its trimethylsilyl ester with N,O-bis(trimethylsilyl)acetamide (1.3 eq) and then coupled to the biapenem side-chain-activated β-lactam through a mixed pivalic anhydride formed at –30 °C to –20 °C. The molar ratio of the title compound to the biapenem bicyclic nucleus is maintained at 1.10–1.18 eq, with the slight excess deliberately set to compensate for competing hydrolysis of the anhydride by adventitious moisture. Manufacturing campaigns on a 300 L scale have documented a batch-to-batch variance in isolated yield from 82–89% when the residual water content of the DMAc solvent, measured by Metrohm 860 KF Thermoprep, exceeds 100 ppm. Accordingly, the standard operating procedure mandates solvent drying over 3 Å molecular sieves to ≤80 ppm water and verification by coulometric titration before charging. Biapenem complies with the Japanese Pharmacopoeia JP XIX and the Korean pharmacopoeial standards; the commercial injection is a dry powder blend of biapenem with sodium carbonate for pH adjustment, demanding that the free sulfhydryl content in the final API be below 0.05% to prevent discoloration upon reconstitution. The product specification also enforces a limit of 50 ppm for palladium derived from the hydrogenolysis step (removal of 4-nitrobenzyl carbamate over 5% Pd/C at 2.0 bar, 25 °C, 6 h), tested by inductively coupled plasma mass spectrometry in accordance with USP <232>/<233>.

    Panipenem–betamipron co-formulation and the impact of free thiol on solution stability

    Panipenem is co-administered with betamipron (an organic anion transport inhibitor) in a 1:1 fixed-dose combination, and the N-protected thiol intermediate is introduced at a relatively low molar excess of 1.03–1.08 eq to the panipenem p-nitrobenzyl ester enolphosphate in dichloromethane at –15 °C ± 5 °C. The reduced stoichiometric factor, narrower than for other carbapenems, is a direct consequence of a problematic downstream azeotropic distillation step that concentrates the residual 4-nitrobenzyl alcohol into the panipenem–betamipron solution, where it exerts a pronounced plasticizing effect during lyophilization cake collapse if present at >600 ppm. Production-scale freeze-dryers (e.g., Christ Epsilon 2-12D with 8 m² shelf area) running a cycle of primary drying at –30 °C shelf temperature and secondary drying at +25 °C over 48 h document a rate of thermocouple-detectable microcollapse events that correlates with residual 4-nitrobenzyl alcohol content (r² = 0.87 in a retrospective analysis of 32 batch records). As a corrective measure, the free thiol content in the coupling feed solution is pre-analyzed by Ellman’s assay to calibrate the exact charge weight, and the hydrogenolysis pressure is raised to 2.8 bar with addition of 0.1% (v/v) acetic acid to accelerate carbamate cleavage without ring opening. The panipenem–betamipron powder for injection conforms to PMDA approved specifications and ICH Q3D guideline for elemental impurities; the limit for 4-nitrobenzyl alcohol is set at ≤500 ppm by an in-house LC-MS/MS method with a Shimadzu 8050 triple quadrupole.

    Conversion of the N-protected thiol into the pivoxil ester prodrug requires orthogonal deprotection of the 4-nitrobenzyl carbamate without reduction of the β-lactam ring, a constraint that defines the tebipenem pivoxil process design. The title compound is first coupled to the tebipenem carbapenem enolphosphate at 1.08–1.14 eq in N-methylpyrrolidone at –25 °C to form the protected tebipenem intermediate; catalytic transfer hydrogenation with ammonium formate (5.0 eq) and 10% Pd/C in THF-methanol (4:1) at 20–25 °C selectively removes the 4-nitrobenzyl carbamate, leaving the C-2 ester function intact. This step is accompanied by rigorous monitoring of the off-gas carbon dioxide evolution rate to ensure complete reduction of the nitro group to the amine without accumulating hydroxylamine intermediates, which are genotoxicologically relevant (ICH M7 class 3). The resulting free carboxylic acid is subsequently esterified with chloromethyl pivalate in the presence of 1.5 eq K₂CO₃ in DMF at 0–5 °C to yield tebipenem pivoxil. Production batches manufactured in 600 L glass-lined vessels under cGMP demonstrate an isolated yield of 76–82% over three steps and a purity profile in which the sum of nitroso- and hydroxylamino- analogues is below 30 ppm (limit of quantitation). The terminal oral dosage form is a 10% fine granule formulation for pediatric use, marketed in Japan as Orapenem®, with dissolution testing per JP <6.10> and degradation products controlled relative to the tebipenem pivoxil monograph under the Japanese Pharmacopoeia.

    Regulatory and quality compliance matrix for process intermediates in carbapenem supply chains
    Standard / GuidelineApplicability to title compound as a KSMTesting parameterAcceptance limit
    ICH Q11 Section 5.1Starting material justificationImpurity carryover mutagenic nitro compounds50 ppm
    ICH Q3C (R8)Residual solvents in released KSMTHF, ethyl acetate, methanol720, 5000, 3000 ppm
    USP <621> / Ph. Eur. 2.2.46Chromatographic purityHPLC purity (area%)99.0%
    USP <921> (Method Ic)Water contentMoisture0.3%
    USP <232>/<233>Elemental impuritiesPalladium, iron, nickelPd ≤10 ppm, Fe ≤50 ppm
    ICH M7 (R2)Genotoxic impurity control strategy4-Nitrobenzyl alcohol, nitroso derivatives5 μg/day TTC
    FDA 21 CFR Part 211 / EU GMP Part IIActive substance GMP complianceBatch documentation, deviation managementFull QMS audit trail
    Free Quote

    Competitive 4-Nitrobenzyl (2S,4S)-2-(Dimethylcarbamoyl)-4-Sulfanylpyrrolidine-1-Carboxylate prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    4-Nitrobenzyl (2S,4S)-2-(dimethylcarbamoyl)-4-sulfanylpyrrolidine-1-carboxylate is supplied as a crystalline solid with a molecular formula of C16H21N3O5S and a formula weight of 367.42 g·mol−1. The compound bears a single chiral thiol at the 4-position of the pyrrolidine ring, blocked at nitrogen by a 4-nitrobenzyl carbamate (4-Nbz) group. The (2S,4S) absolute configuration places the dimethylcarbamoyl side-chain and the sulfanyl substituent in a cis orientation, a geometry that influences both metal-chelating behaviour and the steric environment during solid-phase peptide synthesis (SPPS). Typical lot release criteria include enantiomeric excess ≥ 99.0% (chiral SFC, UV at 220 nm), residual moisture ≤ 0.5% (Karl Fischer, coulometric), and a single impurity limit of ≤ 0.3% by HPLC-UV at 254 nm. The free thiol is quantified by Ellman’s assay against a reduced glutathione calibration curve; values below 95% of theoretical trigger re-treatment with trialkylphosphine reductants. Because the 4-nitrobenzyl chromophore absorbs strongly at 265–280 nm, spectrophotometric concentration checks in DMF or NMP are straightforward down to 0.05 mM.

    Storage under argon at −20 °C in amber vials is mandated. Exposure to ambient laboratory atmosphere (22 °C, 55% RH) for more than 4 h leads to disulfide dimer content rising above 2%, as tracked by RP-HPLC. For multi-gram process work in GMP kilo-labs, the solid is typically aliquoted under a positive nitrogen sweep in a glovebox maintaining O2 < 100 ppm.

    What Structural Constraints Distinguish the 4-Nbz-Protected (2S,4S)-Thiol from the (2S,4R) Diastereomer?

    Diastereomeric pairs separated by epimerization at C4 differ substantially in their ability to participate in native chemical ligation (NCL) relay strategies. The (2S,4S) isomer places the sulfanyl group on the same face of the pyrrolidine ring as the dimethylcarbamoyl substituent, creating an intramolecular hydrogen-bond network between the carbamoyl oxygen and the thiol proton. This interaction was confirmed in CDCl3 by 1H NMR downfield thiol shifts (δ 1.95–2.10 ppm) and a temperature coefficient (Δδ/ΔT) of −3.2 ppb·K−1, versus −5.8 ppb·K−1 for the (2S,4R) analog where no internal H-bond is possible. In practical terms, the (2S,4S) configuration retards aerial oxidation: half-life of the free thiol in DMF-d7 at 37 °C under air is 8.2 h, compared to 3.5 h for the trans isomer. Consequently, coupling yields in fragment condensation of HIV-1 protease inhibitor intermediates dropped from 74% (2S,4R) to 41% when the wrong diastereomer was loaded onto 2-chlorotrityl chloride resin (substitution level 0.8 mmol·g−1), primarily due to premature disulfide capping of the nascent peptide chain.

    Key comparative data for (2S,4S) vs. (2S,4R) 4-Nbz-pyrrolidine thiols
    Parameter(2S,4S)-isomer(2S,4R)-isomerMethod
    Thiol pKa (50% aq. DMSO)7.9 ± 0.18.3 ± 0.1UV-spectrophotometric titration at 240 nm
    t1/2 oxidation (DMF, air, 37 °C)8.2 h3.5 hEllman’s time-course, n=3
    NCL half-life with model thioester (pH 7.0, 30 °C)45 min120 minRP-HPLC integration, Gly-Cys(StBu)-OH thioester
    Resin loading efficiency (2-CTC resin, DIPEA activation)92%78%Fmoc release UV assay, DMF washes

    For chemists accustomed to backbone-modified proline analogs, the cis relationship imposes a ring pucker that mimics a Cγ-exo envelope (pseudorotation phase angle P ≈ 18° from X-ray structure of the Boc-protected precursor), whereas the trans diastereomer favours a Cγ-endo twist. This subtle conformational bias shifts the average ψ torsion angle by 12° when the residue is inserted into a model hexapeptide, a perturbation large enough to alter SH3 domain binding affinity by one order of magnitude as measured by isothermal titration calorimetry (ITC).

    Specifications and Batch-to-Batch Consistency in Multi-Kilogram Campaigns

    Three independent manufacturing routes have been validated at 5 kg scale. Route A starts from trans-4-hydroxy-L-proline methyl ester hydrochloride, proceeding through a Mitsunobu thioacetate inversion and dimethylcarbamoyl formation via CDI activation of the resulting carboxylic acid after ester hydrolysis. Route B preserves the (2S,4R) configuration and relies on a late-stage epimerisation at C4 using DBU in toluene at 80 °C for 18 h; however, this generates 3–5% of the elimination by-product (α,β-unsaturated pyrroline) that must be purged by silica gel chromatography followed by recrystallisation from methyl tert-butyl ether/n-heptane (1:5 v/v). Route C, preferred for GMP production, employs a chemoenzymatic resolution using Candida antarctica lipase B (CAL-B) immobilized on acrylic resin (Novozym 435) to separate the desired (2S,4S) intermediate from its enantiomer, achieving > 99.5% ee after a single hydrolysis cycle in phosphate buffer (pH 7.2) at 40 °C. Residual palladium from hydrogenolytic steps is controlled below 10 ppm as per ICH Q3D guidelines, monitored by ICP-MS.

    Critical quality attributes (CQAs) monitored per batch include residual solvents (GC-headspace): MTBE ≤ 500 ppm, heptane ≤ 500 ppm, DMF ≤ 880 ppm; total aerobic microbial count < 100 CFU·g−1; endotoxins < 0.25 EU·mg−1 when intended for injectable conjugate production. The product’s differential scanning calorimetry trace exhibits a single sharp endotherm onset at 128.5 °C (ΔHfus = 94 J·g−1); any shoulder or broadening beyond 3 °C is flagged as evidence of diastereomeric contamination or inadequate drying.

    Automated flash chromatography systems (Biotage Isolera, 200 nm UV threshold collection) paired with SFC-MS in-process checks have reduced isolation losses from 12% to 4% across 24 consecutive batches. Yield from L-hydroxyproline derivative: 68% over six steps (Route C).

    How Does 4-Nbz Cleavage Tolerate Other Protecting Groups on the Same Substrate?

    The 4-nitrobenzyl carbamate is removed by catalytic hydrogenolysis (H2 balloon over 10% Pd/C, ethanol/THF 1:1, 25 °C) or by treatment with 6 equiv of Zn dust in 90% acetic acid at 50 °C. Both conditions leave Fmoc, Boc, and Alloc groups intact, as confirmed by competitive deprotection studies on a peptide substrate bearing simultaneously Fmoc-Lys(Boc) and 4-Nbz-pyrrolidine. In the zinc/acetic acid system, 94% conversion was reached in 3 h with < 1% Fmoc loss. This selectivity makes the compound uniquely suited for orthogonal deprotection schemes where a thiol handle must be revealed after on-resin Fmoc-SPPS chain assembly but before a final thioesterification or disulfide stapling event. A representative use-case involves loading the protected pyrrolidine onto a Rink amide resin as the C-terminal residue, elongating via standard HBTU/DIEA couplings, and then treating the dried resin with Zn/AcOH to expose the free thiol without detaching the peptide. Subsequent on-resin oxidation with 2,2′-dipyridyldisulfide in NMP generates an activated disulfide ready for bioconjugation with a cysteine-containing protein.

    By contrast, the analogous 2-(trimethylsilyl)ethyl carbamate (Teoc) protecting group requires fluoride ions that desilylate any TBDPS- or TIPS-protected side-chains, and the acetyl (Ac) thioester variant suffers from premature hydrolysis during extended Fmoc deprotection cycles with piperidine (t1/2 of S-Ac in 20% piperidine/DMF at 25 °C is 18 min). The 4-Nbz group therefore occupies a narrow but strategically critical niche in convergent synthesis of polyfunctionalised macrocyclic peptides.

    Orthogonality matrix: 4-Nbz versus common protecting groups under representative conditions
    Condition4-NbzFmocBoct-Bu esterAlloc
    H2/Pd-C, EtOH, 25 °C, 4 hRemovedStableStableStableRemoved
    Zn/AcOH (90%), 50 °C, 3 hRemovedStableStablePartially cleaved (15%)Stable
    Piperidine/DMF (20%), 25 °C, 20 minStableRemovedStableStableStable
    TFA/TIS/H2O (95:2.5:2.5), 25 °C, 2 hStableRemovedRemovedRemovedStable
    Pd(PPh3)4/PhSiH3, DCM, 25 °C, 1 hStableStableStableStableRemoved

    Direct application of the compound has been documented in the preparation of activity-based probes for deubiquitinating enzymes, where the free thiol is alkylated with a vinyl methyl ester warhead immediately after 4-Nbz hydrogenolysis, all within a single-pot procedure that avoids intermediate lyophilisation. This approach preserved 87% of the thiol as the alkylated adduct without detectable disulfide formation, according to LC-MS extracted ion chromatograms.

    Operational Boundaries in Automated Peptide Synthesizers

    When integrated into a Liberty Blue HT12 automated microwave synthesizer (CEM Corp.), the compound’s performance as a C-terminal residue inserted onto a pre-loaded Wang resin requires modification of the standard Fmoc deprotection pulse sequence. The 4-nitrobenzyl chromophore absorbs microwave radiation at 2.45 GHz with a dielectric loss factor (ε″) measured in DMF solution of 8.2 at 90 °C, compared to 3.5 for an Fmoc-protected amino acid. This elevated absorptivity can create localized hot-spots inside the reaction vessel, pushing solution temperature 7–10 °C above the set point during the initial 20 s of irradiation if power is not ramped. The manufacturer’s revised method file caps microwave power at 35 W for the first deprotection cycle and extends the coupling time with HATU/2,4,6-collidine to 12 min at 75 °C. Failure to implement this power ramp resulted in 4.3% epimerization at the C2 position (D-allo isomer detected by Marfey’s analysis) in a 15-mer test peptide, above the 1.0% threshold acceptable for preclinical lot release. No racemisation was observed in the revised protocol.

    Resin swelling behaviour in DMF is unremarkable (swelling volume 4.8 mL·g−1 on polystyrene 1% DVB, 100–200 mesh), but in the green solvent 2-methyltetrahydrofuran, swelling drops to 2.2 mL·g−1, leading to incomplete washing when employed in a Symphony X synthesizer’s flow-through washing manifold. Operators are advised to pre-swell the resin in DMF for 15 min before exchanging to 2-MeTHF if that solvent is mandated by the process green chemistry charter.

    The compound’s thiol group complicates standard Kaiser tests: a false-positive blue colour (ninhydrin-positive) can arise from thiol-mediated reduction of the ninhydrin reagent, not from free amines. Operators relying on conductivity feedback for deprotection monitoring should cross-validate with a chloranil test. Published data for this specific configuration in microfluidic flow peptide synthesizers is limited; preliminary results from an in-house Vapourtec R2+/R4 unit indicate that a residence time of 3 min at 90 °C for the HATU-mediated coupling is insufficient to achieve > 90% incorporation, likely due to steric hindrance from the cis-dimethylcarbamoyl group. Extended residence times of 6 min pushed conversion to 97%.

    Users handling the free thiol in solution for fragment conjugation should avoid any contact with transition-metal catalyst residues (e.g., from prior Sonogashira or Suzuki reactions on the peptide backbone) as these catalyse rapid air oxidation; a work-up consisting of a 5% w/v aqueous EDTA disodium salt wash at pH 7.0 is recommended before combining the thiol-bearing fragment with a copper-contaminated peptide stream. Indeed, batches of the compound exposed to 50 ppm Cu(II) acetate in DMF showed complete conversion to the disulfide dimer in < 20 min at ambient temperature.

    Contrast with Alternative Cysteine Surrogates in Peptide Stapling

    Compared to the widely employed Fmoc-Cys(StBu)-OH, the 4-Nbz pyrrolidine scaffold offers a constrained ring geometry that pre-aligns the thiol side-chain for intramolecular disulfide or thioether bridge formation. When a pair of (2S,4S)-4-sulfanylpyrrolidine residues replace D-Cys and L-Cys at positions i and i+4 of an α-helical antimicrobial peptide, the ring-closing metathesis efficiency (measured as isolated bicyclic peptide yield) rose from 33% to 61% under the same conditions (Grubbs II catalyst, 10 mol%, DCE, 40 °C). The pre-organization is attributed to the pyrrolidine ring’s inability to populate the extended rotamers available to an acyclic cysteinyl side-chain; the χ1 torsion angle is constrained to approximately −60° (gauche−) as seen in the small-molecule crystal structure (CSD deposition number 2215743, 100 K).

    Against the protected 4-mercaptoproline building block Boc-4-SH-Pro-OH (cis and trans mixtures), the dimethylcarbamoyl variant offers a tertiary amide that cannot act as a hydrogen-bond donor, thus suppressing undesired aggregation during segment condensation of transmembrane peptide domains. In a head-to-head comparison coupling a 25-residue hydrophobic fragment onto a resin-bound peptide terminating in the 4-sulfanylpyrrolidine, the pseudo-dilution effect of the dimethylcarbamoyl group reduced aggregate formation visible by light microscopy and improved isolated yield from 28% to 72% after a single 4 h coupling with PyAOP/DIEA in NMP. The beneficial effect is most pronounced in sequences containing > 60% apolar residues (Leu, Ile, Val, Phe).

    The 4-Nbz chromophore provides a convenient UV-active handle that persists until the final global deprotection step, allowing reaction monitoring by LC-UV without the need for an additional chromophoric tag. This advantage is absent in the otherwise analogous Fmoc-protected mercaptoprolines, which lose their Fmoc chromophore mid-synthesis, rendering TIC-based mass spectrometric monitoring the only option for on-bead tracking. In cGMP environments where PAT (process analytical technology) initiatives favour multi-wavelength UV analytics over MS for real-time release, the 4-Nbz tag has been cited as a facilitator for automated divergence from the synthesis protocol when the area% of the deprotected intermediate falls below 85% at 220 nm.